Next Article in Journal
Thienothiophene Scaffolds as Building Blocks for (Opto)Electronics
Next Article in Special Issue
Synthesis of 3-Hydroxy-9H-fluorene-2-carboxylates via Michael Reaction, Robinson Annulation, and Aromatization
Previous Article in Journal / Special Issue
Design, Synthesis, and Photo-Responsive Properties of a Collagen Model Peptide Bearing an Azobenzene
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Synthetic Pathways to Pyrido[3,4-c]pyridazines and Their Polycyclic Derivatives

by
Temitayo Omowumi Alegbejo Price
1,2,
Flavio da Silva Emery
1 and
Wim Dehaen
2,*
1
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences at Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14040-903, SP, Brazil
2
Department of Chemistry, KU Leuven, Celestijnenlaan 200F, 3001 Leuven, Belgium
*
Author to whom correspondence should be addressed.
Organics 2022, 3(4), 430-445; https://doi.org/10.3390/org3040028
Submission received: 31 August 2022 / Revised: 27 September 2022 / Accepted: 10 October 2022 / Published: 18 October 2022
(This article belongs to the Collection Advanced Research Papers in Organics)

Abstract

:
Pyrido[3,4-c]pyridazines are nitrogen-containing scaffolds that have been described as being promising in medicinal chemistry, but they are rather rare chemicals. In this review article, the literature on synthetic pathways towards pyrido[3,4-c]pyridazines is listed exhaustively, first with the bicyclic systems themselves that are obtained starting either from pyridines, pyridazines or other heterocycles. Then, the reports on the related tricyclic derivatives are discussed, again according to the source heterocycle, and finally we mention some examples on polycyclic systems.

1. Introduction

Nitrogen-containing heterocycles play an important role in nature [1] and are also part of the structure of many small molecule drugs. A 2014 study estimated that 59% of the FDA-approved drugs had a nitrogen-containing ring in their structure [2]. However, among those drugs there are clearly much more of the “common” monoheterocycles such as the six-membered pyridine, piperidine and piperazine, or five-membered thiazole, pyrrolidine and imidazoles. Bicyclic structures are somewhat less popular, and in those cephem, penam, indoles and benzimidazoles constitute the majority. Clearly, medicinal chemists have in the past mainly relied on only a few well-known heterocyclic building blocks. W. R. Pitt et al., in “heteroaromatic molecules of the future”, referred to a virtual list of unexplored chemicals selected on synthetic tractability [3]. These 22 bicyclic molecules all had at least one nitrogen in their structure. Among those molecules, one was a derivative of the pyrido[3,4-c]pyridazine 1, the 6-oxo-derivative 2. The synthesis of differently fused pyridopyridazine isomers 1, 3–8 (Figure 1) has been previously reviewed [4], but specific derivatives of 1 or 2 were only briefly mentioned in these texts. In a 2019 follow-up article on the “heteroaromatic molecules of the future”, the literature of 2009–2019 was reviewed [5] and indeed synthetic chemists had risen to the challenge, with reports appearing on 15 of the 22 aforementioned heteroaromatic molecules, but notably the pyridopyrazidinone 2 was not among these, although there had been two theoretical studies on this scaffold [6,7] concerning enhanced inhibition of cytochrome P450s and hydrogen bonding accepting properties, respectively.
With this short review we hope to increase the interest in the heterocycle 1 and its derivatives by exhaustively summarizing synthetic efforts so far. Earlier reviews on “pyridopyridazines” [5,8,9] focus on the other isomers and have mentioned almost nothing on the title subject. As far as we know, this is the first dedicated effort of bringing together all literature on the synthesis of pyrido[3,4-c]pyridazine 1. At the same time, we will also have a detailed look at the related tricyclic and polycyclic analogs of this bicyclic system. Where appropriate, we will also mention any biological properties of the different compounds synthetized.

2. Discussion

2.1. Bicyclic Pyrido[3,4-c]pyridazine Derivatives

2.1.1. Starting from Pyridine Derivatives

One of the earliest procedures towards pyrido[3,4-c]pyridazines led to the synthesis of 10, named 1,2,7-triazanaphthalenes [10], which was based on the Widman-Stoermer cinnoline synthesis, involving a one- pot diazotisation/cyclization sequence of 4-propenyl-3-aminopyridines 9. Unfortunately, only a low yield of 10 (14–17%) was obtained after chromatography. In a later effort [11], the same strategy was applied to obtain the corresponding pyrido[3,4-c]pyridazine-4-one 12b from 4-acetyl-3-aminopyridine 11. This Borsche reaction probably involves the electron rich enol form of the acetyl substituent, to afford (38% yield) a tautomeric equilibrium mixture of 12a,b. This molecule was referred to as a 7-azacinnolin-4(1H)-one. The tautomerism of compound 12 was studied in detail with 1H, 13C and 15N NMR spectroscopy, concluding that the main isomer is indeed 12b in polar solvents such as deuterated DMSO, methanol and water (Scheme 1). Further examples of pyridopyridazinone analogs of 12 prepared by Borsche cyclization of acyl substituted pyridines have been described in the patent literature [12].
The Japp-Klingemann approach was also used to synthesize 3,8-disubstituted pyridopyridazinone from the reaction with 2-chloro-3-aminopyridine 13. The corresponding diazonium salt of 9 is combined with Ethyl-2-methyl-acetoacetate to afford the hydrazone 14, which was then cyclized in polyphosphoric acid to give a low yield of the 8-chloro-3-methyl-pyridopyridazine-4-one 15, which was described as the 4-hydroxy tautomer [13], although probably based on the later study [10] on the analog 12, the structure should be reassigned as the keto tautomer 15 (Scheme 2).
A Hetero-Diels-Alder cycloaddition reaction of 2-vinylpyridines and electron poor azo derivatives was studied by Gurnos et al. [14,15] as an entry into different pyridopyrimidine isomers, including the pyrido[3,4-c]pyrimidine. 2-Vinylpyridine 16 and azodicarboxylates 17 (R = Et, t-Bu) to afford the tetrahydropyridopyrimidines 18 (16% yield for R = t-Bu), that are subsequently deprotected (R = t-Bu) with trifluoroacetic acid (TFA) and oxidized with red mercuric oxide, with a 52% yield for the two final steps leading to the parent compound 1. The cycloaddition reaction is incomplete and possibly polymerization of 16 occurs, explaining the low yield in the first step (Scheme 3).
Starting from N-protected 3-pyridone-4-acetate derivative 19 [16,17] after condensation with hydrazine and oxidation with bromine in acetic acid, the tetrahydropyridopyridazinone 20 is obtained. The latter can then be chlorinated with phosphoryl chloride to the chloro derivative 21, which is used as a convenient building block for further derivatization at the piperidine nitrogen (after deprotection) and/or after reaction of the reactive chlorine, e.g., amine substitutions, and Suzuki arylation (Scheme 4). We do not describe these reactions in detail as they are no longer ring forming reactions but rather standard derivatizations. These derivatives constitute the largest and most studied library of pyridopyridazine analogs in the literature. Different biological properties of these compounds were investigated, including inhibitors of the dipeptidyl peptidase-IV enzyme useful in the treatment of type 2 diabetes [18], histamine H3 receptor binders with CNS activity [16], kinase inhibitors [19], gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) positive allosteric modulators [20] or sphingosine-1-phosphate (S1P) inhibitor activity [21].
The 4-methyl-3-cyano-pyridine-2,6-diones 22 are easily available from the condensation reaction of acetoacetate esters and N-arylcyanoacetamide. Azo coupling with phenyldiazonium salt then gave the hydrazone 23. The latter underwent a one-pot conversion with dimethyl formamide dimethylacetal (DMFDMA) to an enamine 24, followed by cyclocondensation with evolution of dimethylamine, affording the 6,8-dione derivative 25. The reaction takes place either in xylene at reflux (77% yield) or solventless after microwave irradiation (no yield given, Scheme 5) [22].
The N-unsubstituted pyridinedione derivatives 26 were condensed with arylidenemalononitrile in the presence of piperidine base in ethanol solvent at reflux. After the Michael addition of the deprotonated methyl to the electron poor alkene, malononitrile is eliminated by intramolecular substitution. The intermediate 3,4-dihydro compounds 27 are aromatized in situ to the final products 28 (6 examples, 70–75% yield) by ambient oxygen (Scheme 6) [23,24]. A similar entry to analogs of 28 (6-C(CN)2 instead of 6-oxo) by Knoevenagel condensation of 4-methyl-6-dicyanomethylpyridones with aromatic aldehydes was reported [25].

2.1.2. Starting from Pyridazine Derivatives

Pyridopyridazine-3,8-dione 31 was prepared from 4-methyl pyridazine-6-one 29 [26] by a strategy involving condensation of the methyl group with DMFDMA, followed by treatment of enamine intermediate 30 with aniline. On the other hand, the condensation of the 4-ethyl analog of 29 with DMFDMA and subsequent hydrolysis gave ring closure involving the 5-cyano group or the hydrolyzed carboxamide, giving access to isomeric pyrido[3,4-d]pyridazinone derivatives (Scheme 7).
Several variants on this condensation/cyclization strategy starting from pyridazinones have been reported [27,28,29], leading to different pyridopyridazinedione derivatives 3234 (Figure 2). Compounds 32a,b were obtained in poor yield (around 10%) from the condensation of 2-(arylhydrazono) -3-oxobutyrates with two equivalents of ethyl cyanoacetate. Pyridazinones analogous to 29a,b (Ar = 3,4-dimethylphenyl or 3-chloro-4-methylphenyl) were the main isolated products (70% yield), but also the intermediates towards 32a,b, via an aldol-type of condensation of 29 to a second equivalent of the hydrazine and cyclization were obtained. The structure of 32a,b was confirmed by an extensive NMR study [27]. Condensation of 29 (Ar = 4-methylphenyl) with triethyl orthoformate and 4-methylaniline in the presence of piperidine gave further analogs of 31, while condensation of enamine 30 (piperidine instead of dimethylamino) with hydrazine gave the 7-amino derivative 33 [28]. The hydrazones derived from aromatic aldehydes and the carbohydrazide derivative of 29 (Ar = 4-MeOC6H5) were involved in a Knoevenagel condensation/cyclization, affording hydrazones 34 with different combinations of the two aryl groups Ar’ and Ar” [1997PSS]. Further examples of analogues of 3134 prepared similarly from derivatives of 29 have been reported in the literature [30,31,32].
The 4,6-dichloropyridazine-3-carboxylate 35 could be converted via regioselective nucleophilic substitution at the 4-position with t-butyl ethyl malonate and acid-catalyzed decarboxylation of intermediate 36 to the diester 37. Subsequent cyclocondensation of 37 with ammonia in methanol lead to the dihydroxypyridopyridazine 38. This compound was brominated to a trishalogenated pyridopyridazine derivative 39, which then was converted in a number of synthetic steps, involving nucleophilic substitutions at positions 3 and 8 (reactivity towards nitrogen nucleophiles apparently selective in this order) and then Suzuki arylation on the remaining 6-bromide (Scheme 8). The final compounds were tested as HPK1 inhibitors, of interest in the treatment of certain cancers [33].

2.1.3. Starting from Other Building Blocks

Hetero Diels-Alder cycloaddition of 1,2,4,5-tetrazine-3,6vdicarboxylate 40 with the enamine tautomers of cyclic imines such as 5,5-dimethylpyrroline 41 led to fused pyridazine 42 (28% yield) via non-isolable cycloadducts that extruded dinitrogen, then underwent aromatization with liberation of the amine that then formed a lactam with one of the two esters. Likewise, pyridazine 43 was formed in a 52% yield from 2-phenylpyrroline (Scheme 9) [34].

2.2. Tricyclic Derivatives

2.2.1. Benzo Fused Tricyclic Derivatives Starting from Quinolines

4-Acetyl-3-amino-2-phenylquinoline 44 (R = H) was diazotized with nitrous acid and ring closed in alkaline medium, forming the pyridazino[3,4-c]quinoline named 4-hydroxy-10-phenyl-1,2,9-triazaphenanthrene by the authors (more probable the oxo tautomer 45 shown). The Borsche reaction product 45 was obtained in 80% yield on a 10 g scale by precipitation from the reaction mixture. Chlorination of 45 with phosphorous pentachloride gave the chloro derivative 46, which could then be converted to a number of derivatives 47 by nucleophilic substitution [35,36]. Some of the above reactions were also carried out on the 4-propionyl derivative 44 (R = Me). Methylation of the compound 45 occurred regioselectively on one of the pyrazine nitrogens, affording a zwitterionic pyridazinoquinoline 48. Widman-Stoermer reaction starting from 4-alkenyl-3-aminoquinoline substrates as shown before for the synthesis of bicyclic pyridopyridazines 10 analogously gave the tricyclic derivatives 49, in low to good yields [10] (Scheme 10).
Starting from the 3-aminobenzazepine-2,5-dione derivative 50, nitrosation was accompanied by a ring contraction, leading to diazo compound 51, which in acidic medium underwent a Borsche-like cyclization to form tricyclic pyrazinoquinolinedione derivative 52 in almost quantitative yield. However, there seems to be only this one example in the literature of this interesting transformation [37] (Scheme 11).

2.2.2. Benzo Fused Tricyclic Derivatives Starting from Pyridines

Diazotation of 4-aryl-3-aminopyridine derivatives 53 resulted in intramolecular electrophilic substitution of the very electron rich 3,4,5-trimethoxyphenyl substituent to afford the tricyclic pyrido[3,4-c]cinnolines 54 in 64–84% yield, similar to the Widman-Stoermer approach whereas for other less electron rich aryl groups the diazonium salt can be used without such cyclization to prepared azides, that then were thermolysed in xylene to carboline derivatives 55 (Scheme 12) [38].
Photocyclization of 3-phenylazopyridine 56 (R=H) in concentrated sulfuric acid by irradiation at 400–450 nm gave a low yield (19%) of the pyrido[3,4-c]cinnoline 57, together with an even smaller amount of the [3,2-c] fused isomer 58. Both isomers were subjected to vacuum pyrolysis at 800 °C, giving the respective azabiphenylenes 59 (58%) and 60 (34%) after dinitrogen extrusion [39]. In a later study, the hydrochloride salt of the diamino analog of 56 (R = NH2) was irradiated with a 400 W medium pressure mercury vapor lamp in a dilute methanol solution, affording 35% of the product 57 (R = NH2), together with small amounts of several products resulting from N-N cleavage [40] (Scheme 13).
Static pyrolysis of 2,6-diaryl-3-cyano-5-phenylazopyridine 61ac at 400 °C gave low yields of pyridocinnolines 62ac (3–14%) next to N-N reduction products 63ac (20–51%) and aniline 64 (21–57%) (Scheme 14) [41].
In an early study, formazan 65 was oxidized to a tetrazolium salt 66, which upon irradiation with an ultraviolet high pressure immersion lamp PL 313 at 25° cyclized to the fused tetrazolium salt 67. The reduction in the latter gave the parent pyridocinnoline 57 (R = H) [42] (Scheme 15).

2.2.3. Benzo Fused Tricyclic Derivatives Starting from Cinnolines, Pyridazines or Tetrazines

Moreover, 3-Bromocinnoline-4-one 68 could be substituted with copper cyanide to the nitrile 69, and the latter was chlorinated to 4-chloro-3-cyanocinnoline 70. Nucleophilic aromatic substitution of 70 with acetylacetone, and base-catalysed hydrolysis to the amide and ring closure then gave the pyridocinnolinone 71 in a 38% yield [43] (Scheme 16).
Reductive cyclization of 4-(2-nitrophenyl) -pyridazine-3-carboxylate esters 72 with iron in acetic acid gave the lactams 73. However, when the reduction was carried out with zinc and ammonium chloride, the hydroxamic acid derivative 74 was isolated. (Scheme 17). The inhibition of soybean 5-lipoxygenase was tested for the latter compounds and found to be only weak [44,45].
Inverse Diels-Alder reaction of N-methylindole 74 with 1,2,4,5-tetrazine-3,6-d-carboxylate 40 in dichloromethane at reflux gave after nitrogen extrusion a ring opening/ring closure sequence, giving another entry into pyridazoquinolones 75. [46] (Scheme 18). The reaction was also carried out on 2,2′-bis-N-methylindolyl, affording protein kinase C inhibitors [47].

2.2.4. Heterocycle Fused Tricyclic Derivatives

Reduction of 2,2′-dinitro-4,4′-bipyridyl 76 with sodium sulfide initially led to a 3: 1 mixture of bispyridopyridazine 77 (59% yield) and its N-oxide 78. The latter could be deoxygenated with iron at 250 °C. [48] The reduction with sodium sulfide could be optimized later to give 89% of only 77. Reduction of 76 with arsenious oxide gave the N, N’-oxide 79, whereas the Pd/C catalyzed hydrogenation gave the diamine 80 [49]. The bispyridopyridazine 77 was used in these and many subsequent studies for the synthesis of 2,7-diazabiphenylene 81 in a 57% yield [50] by extrusion of nitrogen under different vacuum pyrolysis conditions. The bispyridopyridazine 77 can also be prepared from diamine 80 by diazotation in a 38% yield [51]. The reaction sequence in Scheme 19 was also used to prepared unsymmetrically fused bispyridopyridazine 82 by reductive cyclization of the corresponding ortho, ortho’-dinitro-2,4′-bipyridine [52].
Widman-Stoermer type cyclization of 3-pyridyldiazonium salts involving the electrophilic substitution of electron rich five membered rings placed at the 4-position, similar to Scheme 12, was carried out successfully, affording different pyridopyridazines fused with thiophens (83, 85% yield and 84, 72% yield), pyrroles (85, 77% yield) and furans (86, 76% yield) [53,54] (Figure 3).
An isomeric pyrrolo fused pyridopyridazine 89 was prepared by reducing 5-nitro-4-acetyl-8-azaindole 87 and applying the Borsche cinnoline reaction on the obtained amine 88 after nitrosation and cyclization. Chlorination of 88 with phosphoryl chloride in chlorobenzene gave the building clock 90, that was used in a study of treatment of diseases that are mediated by JAK activity [55] (Scheme 20).
A 1,2,4-triazolo fused pyridopyridazine has been reported. The enamine 91, prepared from 29 (Ar = 4-Me-phenyl) by condensation with triethyl orthoformate and piperidine, was condensed with 2-cyanoacetohydrazide by heating at reflux in dimethyl formamide solution, to afford tricyclic 92 in a 71% yield [28] (Scheme 21).
An interesting diastereoselective synthesis of partially reduced triazoledione fused pyridopyridazines 95 was reported by Diels-Alder cycloaddition of 4-vinyl-1,2,5,6-tetrahydropyridine dienes 93 with N-phenyl-1,2,4-triazoledione dienophile 94. The reactions proceeded within a few hours at low temperature with good to excellent chemical yields (7 examples, 67–97%) and very good diastereoselectivities (>20:1) [56] (Scheme 22).
A special case of a pyridine fused pyridopyridazine salt 98, called the 8a-azonia-3,4-diazaphenanthrene cation by the authors, was available in a 36% yield as the only product obtained after hetero- Diels-Alder cycloaddition of 3,6-(2-pyridyl)-1,2,4,5-tetrazine 96 with cis-3,4-dichlorocyclobutene. The expected product 97 was not isolated, but under the reaction circumstances it is probable that ring opening of cyclobutyl/ring closure involving pyridine nitrogen occurs, finally affording 98. The structure of the salt 98 was proven unambiguously by single crystal X-ray crystallographic analysis [57] (Scheme 23).

2.3. Polycyclic Derivatives

Pentacyclic analogs 99 or their N-oxide analogs could be prepared from bis(nitroquinolines) similarly to the chemistry in Scheme 19 [48]. Thermolysis of 99 led to the condensed derivative 100 [49]. In a series of publications, thebaine or other morphinanediene derivatives were combined in a room temperature Diels-Alder reaction with diazodicarboxylate, triazole dione or other cyclic diazo dienophiles, to afford diverse complex polycyclic derivatives 101 that strictly speaking contain a reduced pyridopyridazine but are somewhat out of the scope of this review. A β-face attack of the dienophile occurs in the case of the natural products containing a furan ring, whereas the derivatives with opened furan favor α-attack [58,59,60,61]. No biological properties seem to have been reported for these compounds (Figure 4).

3. Conclusions

The pyrido[3,4-c]pyridazines and their fused derivatives remain rare chemicals and the reports that have appeared so far are widely scattered, with often only a few examples given in low or only fair yield without any follow-up studies to widen the scope. Therefore, applications of this scaffold as biologically active compounds have been limited. To make further advances and to realize the recognized potential of this moiety in medical chemistry, more attention should be given in the future to apply new advances in organic synthesis, including transition metal catalyzed reactions, as well as organocatalytic, photocatalytic and electrocatalytic processes. We hope to meet this challenge in following reports of our laboratories; it was also our aim to have stimulated further research by our colleagues in the field of heterocyclic and medicinal chemistry.

Author Contributions

Conceptualization, W.D.; writing—original draft preparation, W.D. and T.O.A.P.; writing—review and editing, W.D. and F.d.S.E.; funding acquisition, W.D. and F.d.S.E. All authors have read and agreed to the published version of the manuscript.

Funding

The authors would like to acknowledge FAPESP/FWO for a bilateral grant (grant nr#2018/10966-3), São Paulo Research Foundation (FAPESP) and FWO. Furthermore, FWO is thanked for the grant W000620N.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

TOAP would like to acknowledge TWAS-CNPq (163813/2018-3) for a PhD fellowship.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Walsh, C.T. Nature loves nitrogen heterocycles. Tetrahedron Lett. 2015, 56, 3075–3081. [Google Scholar] [CrossRef]
  2. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. J. Med. Chem. 2014, 57, 10257–10274. [Google Scholar] [CrossRef] [PubMed]
  3. Pitt, W.R.; Parry, D.M.; Perry, B.G.; Groom, C.R. Heteroaromatic Rings of the Future. J. Med. Chem. 2009, 52, 2952–2963. [Google Scholar] [CrossRef] [PubMed]
  4. Wojcicka, A.; Nowicka-Zuchowska, A. Synthesis and Biological Activity of Pyridopyridazine Derivatives: A Mini Review. Mini-Rev. Org. Chem. 2018, 16, 3–11. [Google Scholar] [CrossRef]
  5. Thorimbert, S.; Botuha, C.; Passador, K. ‘Heteroaromatic Rings of the Future’: Exploration of Unconquered Chemical Space. Synthesis 2019, 51, 384–398. [Google Scholar] [CrossRef]
  6. Leach, A.G.; Kidley, N.J. Quantitatively Interpreted Enhanced Inhibition of Cytochrome P450s by Heteroaromatic Rings Containing Nitrogen. J. Chem. Inf. Model. 2011, 51, 1048–1063. [Google Scholar] [CrossRef]
  7. Graton, J.; le Questel, J.Y.; Maxwell, P.; Popelier, P. Hydrogen-Bond Accepting Properties of New Heteroaromatic Ring Chemical Motifs: A Theoretical Study. J. Chem. Inf. Model. 2016, 56, 322–334. [Google Scholar] [CrossRef] [Green Version]
  8. Yamamoto, Y.; Shinkai, I. (Eds.) Product Class 18: Pyridopyridazines. In Science of Synthesis, 16: Category 2, Hetarenes and Related Ring Systems; Thieme: New York, NY, USA, 2004. [Google Scholar] [CrossRef]
  9. Ibrahim, M.A.; Elmenoufy, A.H.; Elagawany, M.; Ghoneim, M.M.; Moawad, A. “Pyridopyridazine”: A Versatile Nucleus in Pharmaceutical Field. J. Biosci. Med. 2015, 3, 59–66. [Google Scholar] [CrossRef] [Green Version]
  10. Atkinson, C.M.; Biddle, B.N. Triazaphenanthrenes. Part VI. Further observations on the Widman-Stoermer and Borsche reactions. J. Chem. Soc. C 1966, 2053–2060. [Google Scholar] [CrossRef]
  11. Stockmann, V.; Primpke, S.; Fiksdahl, A. 7-Azacinnolin-4(1H)-one preparation and NMR studies of tautomery. J. Heterocycl. Chem. 2011, 48, 737–741. [Google Scholar] [CrossRef]
  12. Bundy, G.L. Heterocycle Carboxamides as Antiviral Agents (WO 02/04444); World Intellectual Property Organisation: Geneva, Switzerland, 2002. [Google Scholar]
  13. Kochhar, M.M. 8-chloro-4-hydroxy-3-methyl-pyrido[3,4-c]pyridazine. J. Heterocycl. Chem. 1969, 6, 977–978. [Google Scholar] [CrossRef]
  14. Jones, G.; Rafferty, P. A synthesis of annulated pyridazines by cycloaddition of azodicarboxylates to vinylpyridines. Tetrahedron Lett. 1978, 19, 2731–2734. [Google Scholar] [CrossRef]
  15. Jones, G.; Rafferty, P. The synthesis of annulated pyridazines by cycloaddition of azodicarboxylates to vinyl heterocycles. Tetrahedron 1979, 35, 2027–2033. [Google Scholar] [CrossRef]
  16. Gao, Y. Piperazinyl Oxoalkyl Tetrahydroisoquinolines and Related Analogues (WO 2007/106349); World Intellectual Property Organization: Geneva, Switzerland, 2007. [Google Scholar]
  17. Zhao, L.; Jin, L.; Jin, Y. 5,6,7,8-Tetrahydro-2H-Pyridineo [3,4-c] Pyridine Synthesis Method of Azine-3-Ketones (CN 102924452 A); State Intellectual Property Office of the People’s Republic of China: Beijing, China, 2013. [Google Scholar]
  18. Ashton, W.T.; Caldwell, C.G.; Duffy, J.L.; Mathvink, R.J.; Wang, L.; Weber, A. 3-Amino-4-Phenylbutanoic Acid Derivatives as Dipeptidyl Peptidase Inhibitors for the Treatment or Prevention of Diabetes (WO 2004/069162); World Intellectual Property Organization: Geneva, Switzerland, 2004. [Google Scholar]
  19. Wan, H.; Geng, M.; Yu Cheng, C. A Class of Compounds with Kinase Inhibitory Activity, Preparation Method and Uses (201610383073.2); State Intellectual Property Office of the People’s Republic of China: Beijing, China, 2016. [Google Scholar]
  20. Szabo, G.; Potor, A. Naphthyridine and Pyrido[3,4-c]pyridazine Derivatives as GABAa α5 Receptor Modulators (WO 2021/191838); World Intellectual Property Organization: Geneva, Switzerland, 2021. [Google Scholar]
  21. Lange, U.; Ochse, M.; van der Kam, E.; van Bergeijk, J.; Turner, S.; Oellien, F.; Walleser, P.; Amberg, W.; Hornberger, W.; Geneste, H.; et al. Fused Heterocyclic Compounds as SlP Modulators (US 2017/0057966); United States Patent Application Publication: Ludwigshafen, Denmark, 2017. [Google Scholar]
  22. Al-Mousawi, S.M.; Abdelhamid, I.A.; Moustafa, M.S. Alkylazinylcarbonitriles as building blocks in organic synthesis: Synthesis of 3-amino-7-arylhyrazonothieno-7H-[3,4-c]-pyridine-4,6-diones and pyrido-[3,4-c]-pyridazine-5-carbonitrile. Arkivoc 2007, 2007, 213–221. [Google Scholar] [CrossRef] [Green Version]
  23. Barsy, M.A. Studies on Polyfunctionalised Heteroaromatics: Synthesis of Several New Cinnoline and Pyrido[3,4-c]pyridazine Derivatives. J. Chin. Chem. Soc. 2000, 47, 951–955. [Google Scholar] [CrossRef]
  24. El Rady, E.A.; Barsy, M.A. A Convenient and Facile Synthesis of Pyridine, Pyridazine, Pyrimido[4,5-c]pyridazine, Pyrido[3,4-c]pyridazine, 1,6-Naphthyridine and Phthalazine Derivatives. ChemInform 2006, 37, 243–248. [Google Scholar] [CrossRef]
  25. Elnaghi, M.H.; Hassan, M.E.; Elmaghraby, M.A.; Abdul Aziz, M.A. Studies on alkylheteroaromatics: A novel synthesis of pyrido[3,4-c]pyridazine derivatives. Sci. Technol. Bull. 1992, 13, 45–50. [Google Scholar]
  26. Al-Awadhi, H.; Al-Omran, F.; HElnagdi, M.; Infantes, L.; Foces-Foces, C.; Jagerovic, N.; Elguero, J. New synthetic approaches to condensed pyridazinones: Alkylpyridazinyl carbonitriles as building blocks for the synthesis of condensed pyridazinones. Tetrahedron 1995, 51, 12745–12762. [Google Scholar] [CrossRef]
  27. Laihia, K.; Kolehmainen, E.; Wegelius, E.; Miltsov, S.; Nikiforov, V.; Karavan, V. NMR Spectroscopic and X-ray Structural Characterization of Two Diaryl Derivatives of (4-Cyano-6-methyl-3,8-dioxo-2,3,5,6,7,8-hexahydropyrido[3,4-c] Pyridazin-6-yl)hydrazono-acetic acid Ethyl Ester. Heterocycl. Commun. 2004, 10, 35–42. [Google Scholar] [CrossRef]
  28. Darwish, E.S.; Abdelrahman, M.A.; Salaheldin, A.M. Enamines in Heterocyclic Synthesis: A Novel Simple and Efficient Route to Condensed Pyridazines. Z. Für Nat. B 2011, 66, 597–602. [Google Scholar] [CrossRef]
  29. Erian, A.W.; Elkholy, Y.M.; Al-arab, E.E.; Elnagdf, M.H. Polyfunctionally Substituted Heterocycles: Synthesis of New Polyfunctionally Substituted Phthalazines, Pyrido[3,4-c]pyridazines and Pyrazolo[3,4-c]pyridazines. Phosphorus Sulfur Silicon Relat. Elem. 1997, 122, 133–141. [Google Scholar] [CrossRef]
  30. Manhi, F.M.; Zayed, S.E.; Ali, F.A.; Elnagdi, M.H. Studies with Polyfunctionally Substituted Heterocycles: Novel Syntheses of Pyrido[4,3-d]pyridazines and of Pyrido[3,4-d]pyridazines. Collect. Czechoslov. Chem. Commun. 1992, 57, 1770–1774. [Google Scholar] [CrossRef]
  31. Elghandour, A.H.H.; Hussein, A.H.M.; Elnagdi, M.H.; Harb, A.F.A.; Metwally, S.A.M. Polyfunctionally Substituted Heterocycles: Synthesis of new polyfunctionally substituted phthalazines, thieno[3,4-d]pyridazines and pyrido [3,4-c]pyridazines. J. Fur Prakt. Chem. Chem.-Ztg. 1992, 334, 723–726. [Google Scholar] [CrossRef]
  32. Hussein, A.M.; Atalla, A.A.; El-dean, A.M.K. Novel Synthesis of Pyridopyridazine, Pyrrolopyridazine and Some Pyridazine Derivatives. Pol. J. Chem. 1995, 69, 1642. [Google Scholar]
  33. Hao, X. Cinnolines as Inhibitors of HPK 1 (WO 2021/004535); World Intellectual Property Organization: Geneva, Switzerland, 2021. [Google Scholar]
  34. Berger, U.; Dannhardt, G.; Obergrusberger, R. Diels-Alder-Reaktionen mit cyclischen Iminen, 3. Mitt. Cycloaddition von Iminen an Tetrazine. Arch. Pharm. 1982, 315, 428–437. [Google Scholar] [CrossRef]
  35. Atkinson, C.M.; Mattocks, A.R. 733. Triazaphenanthrenes. Part II. Derivatives of 10-phenyl- 1:2:9-triazaphenanthrene. J. Chem. Soc. 1957, 3722–3726. [Google Scholar] [CrossRef]
  36. Atkinson, C.M.; Mattocks, A.R. 320. Triazaphenanthrenes. Part V. The site of quaternisation in some triazaphenanthrene methiodides. J. Chem. Soc. 1962, 1671–1678. [Google Scholar] [CrossRef]
  37. Cajipe, G.J.B.; Landen, G.; Semler, B.; Moore, H.W. Reaction of aminoquinones and related vinylogous amides with nitrous acid. Synthesis and chemistry of cyclic diazo ketones. J. Org. Chem. 1975, 40, 3874–3878. [Google Scholar] [CrossRef]
  38. Proshchenkova, V.; Shuvalov, V.Y.; Glyzdinskaya, L.V.; Fisyuk, A.S.; Chernenko, S.A.; Khvostov, M.V.; Tolstikova, T.G.; Vorontsova, M.; Sagitullina, G.P. Synthesis of 4-Ethoxycarbonyl(cyano)-β-Carbolines via Thermolysis of 4-Aryl-3(5)-Azidopyridine Derivatives and the Study of their Optical and Hypoglycemic Properties. Chem. Heterocycl. Compd. 2021, 57, 187–198. [Google Scholar] [CrossRef]
  39. Barton, J.; Walker, R. Synthesis of the monoazabiphenylenes. Tetrahedron Lett. 1975, 16, 569–572. [Google Scholar] [CrossRef]
  40. Iqbal, J.; Gupta, A.; Husain, A. Photochemistry of phenazopyridine hydrochloride. Pharmazie 2006, 61, 747–750. [Google Scholar] [PubMed]
  41. Al-Awadi, N.A.; Ibrahim, Y.A.; Elnagdi, M.; Adam, A.Y.; John, E. Gas-phase pyrolysis of arylazonicotinates and nicotinonitriles: Routes towards new aminopyridine and pyrido[3,4-c]cinnoline derivatives. J. Anal. Appl. Pyrolysis 2017, 124, 602–609. [Google Scholar] [CrossRef]
  42. Jerchel, D.; Fischer, H. 2.3-Azadiphenylen-tetrazoliumsalze und Triazaphenanthrene. Chem. Ber. 1956, 89, 563–570. [Google Scholar] [CrossRef]
  43. Ames, D.E.; Byrne, C.J.A. Cinnolines. Part XVII. Reactions of 4-chlorocinnoline-3-carbonitrile and preparation of 2,3-dihydro-3-imino-1H-pyrazolo[4,3-c]cinnolines. J. Chem. Soc. Perkin Trans. 1 1976, 6, 592. [Google Scholar] [CrossRef]
  44. Goerlitzer, K.; Behrje, H. Furo-, Pyrrolo- and Pyridazino(3,4-c)quinolines. Pharmazie 1996, 51, 528–534. [Google Scholar] [CrossRef]
  45. Goerlitzer, K.; Fabian, J.; Jones, P.G.; Frohberg, P.; Drutkowski, G. Pyridazino[3,4-c]quinolines and Pyridazino[4,5-c]quinolines—Synthesis and Investigation of Lipoxygenase Inhibition. Pharmazie 2002, 57, 362–371. [Google Scholar] [CrossRef]
  46. Seitz, G.; Kämpchen, T. Inverse” Diels-Alder-Additionen, 4. Mitt.: π-Elektronenreiche, benzokondensierte Heteroaromaten als „inverse” Dienophile. Arch. Der Pharm. 1976, 309, 679–681. [Google Scholar] [CrossRef]
  47. Pindur, U.; Kim, Y.S.; Schollmeyer, D. Cyclization Reactions of 2,2’-Bis-N-methylindolyl to Potential Protein Kinase C Inhibitors. Heterocycles 1994, 38, 2267. [Google Scholar] [CrossRef]
  48. MacBride, J.A.H. Synthesis of 2,7-diazabiphenylene by thermal extrusion of nitrogen from 2,7,9,10-tetra-azaphenanthrene. J. Chem. Soc. Chem. Commun. 1974, 9, 359b. [Google Scholar] [CrossRef]
  49. Kanoktanaporn, S.; MacBride, J.A.H. Preparation of ring-fused pyridazines by reduction of 3,3′-dinitro-4,4′-bipyridyl and 3,3′-dinitro-4,4′-biquinolyl. J. Chem. Soc. Perkin Trans. 1 1978, 1126–1131. [Google Scholar] [CrossRef]
  50. Kanoktanaporn, S.; MacBride, J.A.A.; King, T.J. Biphenylenes and Heterocyclic Analogs of Biphenylene. Part II. Preparation of f 2,7-Diazabiphenylene, its Quaternary Salts, and an Unstable Angular Dibenzo-derivative; X-ray Crystal Structure of 2-Allyl-2-azonia-7-azabiphenylene bromi. J. Chem. Res. Synop. 1980, 11, 2911–2940. [Google Scholar] [CrossRef]
  51. Kaczmarek, U. Bipyridines. XIX. Synthesis of some novel 2,7,9,10-Tetraazaphenanthrene derivatives. J. Fuer Prakt. Chem. 1987, 329, 592–598. [Google Scholar] [CrossRef]
  52. MacBride, J.; Wright, P.H.; Wakefield, B.J. Synthesis of 1.6-Diazabiphenylene by Flash Vacuum Pyrolysis of 2,5,9,10-tetra-azaphenanthrene; NMR Evidence for Rehybridisation in Biphenylenes. Tetrahedron Lett. 1981, 22, 4545–4548. [Google Scholar] [CrossRef]
  53. Stockmann, V.; Fiksdahl, A. Preparation of new pyrido[3,4-b]thienopyrroles and pyrido[4,3-e]thienopyridazines. Tetrahedron 2008, 64, 7626–7632. [Google Scholar] [CrossRef]
  54. Stockmann, V.; Eriksen, K.L.; Fiksdahl, A. Preparation of novel pyridine-fused tris-heterocycles; pyrido[4,3-e]pyrrolo-/pyrido[4,3-e]furano[2,3-c]pyridazines and pyrido[3,4-b]pyrrolo[3,2-d]pyrrole. Tetrahedron 2008, 64, 11180–11184. [Google Scholar] [CrossRef]
  55. Barawkar, D.; Bende, T.; Zahler, R.; Bandyopadhyay, A.; Sarangthem, R.S.; Doshi, J.; Waman, Y.; Jadhav, R.; Singh, U.P. Substituted Fused Tricyclic Compounds, Compositions and Medicinal Applications Thereof (WO 2012/127506); World Intellectual Property Organization: Geneva, Switzerland, 2012. [Google Scholar]
  56. Llobat, A.; Escorihuela, J.; Sedgwick, D.M.; Rodenes, M.; Román, R.; Soloshonok, V.A.; Han, J.; Medio-Simón, M.; Fustero, S. The Ruthenium-Catalyzed Domino Cross Enyne Metathesis/Ring-Closing Metathesis in the Synthesis of Enantioenriched Nitrogen-Containing Heterocycles. Eur. J. Org. Chem. 2020, 4193–4207. [Google Scholar] [CrossRef]
  57. Elix, J.A.; Sterns, M.; Wilson, W.S.; Warrener, R.N. Preparation and X-ray structure of the 8a-azonia-3,4-diazaphenanthrene cation. J. Chem. Soc. D Chem. Commun. 1971, 9, 426b. [Google Scholar] [CrossRef]
  58. Merz, H.; Pook, K.H. Reaktionen des thebains mit azodicarbonsäureestern. Tetrahedron 1970, 26, 1727–1741. [Google Scholar] [CrossRef]
  59. Giger, R.; Rubinstein, R.; Ginsburg, D. Synthesis and reactions of the Diels-Alder adduct of thebaine with 4-phenyl-1,2,4-triazoline-3,5-dione. Tetrahedron 1973, 29, 2387–2391. [Google Scholar] [CrossRef]
  60. Marton, J.; Szabó, Z.; Csorvássy, I.; Simon, C.; Hosztafi, S.; Makleit, S. Reaction of morphinan-6,8-dienes with azadienophiles. Tetrahedron 1996, 52, 2449–2464. [Google Scholar] [CrossRef]
  61. Csutoras, C.; Berenyi, S.; Czako, B.; Makleit, S. Syntheses and transformations of novel nitrogen and sulfur containing morphinanedienes. Mon. Fur Chem. Chem. Mon. 1997, 128, 1267–1273. [Google Scholar] [CrossRef]
Figure 1. Pyrido[3,4-c]pyridazine 1, oxo derivative 2 and isomers 38.
Figure 1. Pyrido[3,4-c]pyridazine 1, oxo derivative 2 and isomers 38.
Organics 03 00028 g001
Scheme 1. Widman-Stoermer synthesis of pyrido[3,4-c]pyridazine derivatives.
Scheme 1. Widman-Stoermer synthesis of pyrido[3,4-c]pyridazine derivatives.
Organics 03 00028 sch001
Scheme 2. Synthesis of pyridopyrazin-8-one by acid-catalyzed cyclization of hydrazone.
Scheme 2. Synthesis of pyridopyrazin-8-one by acid-catalyzed cyclization of hydrazone.
Organics 03 00028 sch002
Scheme 3. The parent pyrido[3,4-c]pyridazine by cycloaddition/deprotection/oxidation.
Scheme 3. The parent pyrido[3,4-c]pyridazine by cycloaddition/deprotection/oxidation.
Organics 03 00028 sch003
Scheme 4. 5,6,7,8-Tetrahydro derivatives of pyridopyridazines from 3-piperidones.
Scheme 4. 5,6,7,8-Tetrahydro derivatives of pyridopyridazines from 3-piperidones.
Organics 03 00028 sch004
Scheme 5. 5-Cyano derivatives of pyridopyridazine-6,8-diones.
Scheme 5. 5-Cyano derivatives of pyridopyridazine-6,8-diones.
Organics 03 00028 sch005
Scheme 6. Synthesis of pyridopyridazine-6,8-diones from arylidene-malononitrile and N-substituted pyrimidinedione.
Scheme 6. Synthesis of pyridopyridazine-6,8-diones from arylidene-malononitrile and N-substituted pyrimidinedione.
Organics 03 00028 sch006
Scheme 7. Synthesis of pyrido[3,4-c]pyridazine-3,8-dione.
Scheme 7. Synthesis of pyrido[3,4-c]pyridazine-3,8-dione.
Organics 03 00028 sch007
Figure 2. Miscellaneous pyridopyridazine-3,8-dione derivatives.
Figure 2. Miscellaneous pyridopyridazine-3,8-dione derivatives.
Organics 03 00028 g002
Scheme 8. Synthesis of 3-chloro-6,8-dibromopyridopyridazine.
Scheme 8. Synthesis of 3-chloro-6,8-dibromopyridopyridazine.
Organics 03 00028 sch008
Scheme 9. From tetrazines to pyridopyridazines.
Scheme 9. From tetrazines to pyridopyridazines.
Organics 03 00028 sch009
Scheme 10. Borsche and Widman-Stoermer reactions leading to pyridazinoquinoline derivatives.
Scheme 10. Borsche and Widman-Stoermer reactions leading to pyridazinoquinoline derivatives.
Organics 03 00028 sch010
Scheme 11. Pyridazinoquinolines via diazotation, ring contraction and cyclization.
Scheme 11. Pyridazinoquinolines via diazotation, ring contraction and cyclization.
Organics 03 00028 sch011
Scheme 12. Cyclization of diazonium salts to pyridocinnolines.
Scheme 12. Cyclization of diazonium salts to pyridocinnolines.
Organics 03 00028 sch012
Scheme 13. Pyridocinnolines by photocyclization.
Scheme 13. Pyridocinnolines by photocyclization.
Organics 03 00028 sch013
Scheme 14. Pyridocinnolines by static pyrolysis.
Scheme 14. Pyridocinnolines by static pyrolysis.
Organics 03 00028 sch014
Scheme 15. Synthesis of pyridocinnoline by reduction in tetrazolium salt.
Scheme 15. Synthesis of pyridocinnoline by reduction in tetrazolium salt.
Organics 03 00028 sch015
Scheme 16. Benzofused tricyclic derivatives from cinnolines.
Scheme 16. Benzofused tricyclic derivatives from cinnolines.
Organics 03 00028 sch016
Scheme 17. Reductive cyclization leading to pyridazoquinolinones.
Scheme 17. Reductive cyclization leading to pyridazoquinolinones.
Organics 03 00028 sch017
Scheme 18. Inverse Diels-Alder reaction leading to pyridazoquinolinones.
Scheme 18. Inverse Diels-Alder reaction leading to pyridazoquinolinones.
Organics 03 00028 sch018
Scheme 19. Synthesis of Bispyridopyridazines.
Scheme 19. Synthesis of Bispyridopyridazines.
Organics 03 00028 sch019
Figure 3. Pyridopyridazines fused with five-membered rings.
Figure 3. Pyridopyridazines fused with five-membered rings.
Organics 03 00028 g003
Scheme 20. Pyrrolo fused pyridopyridazine.
Scheme 20. Pyrrolo fused pyridopyridazine.
Organics 03 00028 sch020
Scheme 21. 1,2,4-Triazolo fused pyridopyridazine.
Scheme 21. 1,2,4-Triazolo fused pyridopyridazine.
Organics 03 00028 sch021
Scheme 22. Triazolo fused (reduced)pyridopyridazines by Diels-Alder reaction.
Scheme 22. Triazolo fused (reduced)pyridopyridazines by Diels-Alder reaction.
Organics 03 00028 sch022
Scheme 23. Pyridine fused pyridopyridazine salt.
Scheme 23. Pyridine fused pyridopyridazine salt.
Organics 03 00028 sch023
Figure 4. Different polycyclic pyridopyridazine derivatives.
Figure 4. Different polycyclic pyridopyridazine derivatives.
Organics 03 00028 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Alegbejo Price, T.O.; Emery, F.d.S.; Dehaen, W. Synthetic Pathways to Pyrido[3,4-c]pyridazines and Their Polycyclic Derivatives. Organics 2022, 3, 430-445. https://doi.org/10.3390/org3040028

AMA Style

Alegbejo Price TO, Emery FdS, Dehaen W. Synthetic Pathways to Pyrido[3,4-c]pyridazines and Their Polycyclic Derivatives. Organics. 2022; 3(4):430-445. https://doi.org/10.3390/org3040028

Chicago/Turabian Style

Alegbejo Price, Temitayo Omowumi, Flavio da Silva Emery, and Wim Dehaen. 2022. "Synthetic Pathways to Pyrido[3,4-c]pyridazines and Their Polycyclic Derivatives" Organics 3, no. 4: 430-445. https://doi.org/10.3390/org3040028

APA Style

Alegbejo Price, T. O., Emery, F. d. S., & Dehaen, W. (2022). Synthetic Pathways to Pyrido[3,4-c]pyridazines and Their Polycyclic Derivatives. Organics, 3(4), 430-445. https://doi.org/10.3390/org3040028

Article Metrics

Back to TopTop